Q32 Bio (QTTB)

Executive Summary

Q32 Bio is a clinical-stage biotechnology company pioneering targeted immune therapeutics to rebalance the immune system in autoimmune and inflammatory diseases. The company's lead asset, bempikibart (ADX-914), is a dual inhibitor of IL-7 and TSLP pathways, currently in Phase 2 clinical trials for alopecia areata and atopic dermatitis. Bempikibart has the potential to address significant unmet need in these indications by modulating both innate and adaptive immune responses. Additionally, Q32 Bio is advancing a novel platform for tissue-targeted complement inhibitors, with ADX-097 previously evaluated for complement-mediated diseases, though the Phase 2 trial in IgA nephropathy was withdrawn. Q32 Bio went public via a SPAC merger in 2025 and trades under the ticker QTTB. The company's near-term value hinges on the successful development of bempikibart, with upcoming data readouts that could de-risk its pipeline and support regulatory advancement.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 topline data for bempikibart in alopecia areata50% success
• Q2 2026Presentation of Phase 2 data for bempikibart in atopic dermatitis70% success
• H2 2026Initiation of new clinical trial for tissue-targeted complement inhibitor40% success